Everolimus

Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole. Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.

• Heart Transplant Rejection
• Kidney Transplant Rejection
• Liver Transplant Rejection
• Progressive Neuroendocrine Tumors of pancreatic origin
• Renal angiomyolipoma, tuberous sclerosis complex
• Subependymal giant cell astrocytoma, tuberous sclerosis complex
• Waldenstrom's Macroglobulinemia Refractory
• Advanced Carcinoid tumor
• Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin
• Locally advanced lung origin Progressive Neuroendocrine Tumors
• Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors
• Metastatic lung origin Progressive Neuroendocrine Tumors
• Refractory Advanced Renal Cell Carcinoma
• Refractory, advanced Breast cancer
• Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors
• Unresectable lung origin Progressive Neuroendocrine Tumors